Table 6. Growth inhibitory drug effects in cell lines containing KIT mutations identified in thymic carcinomas.

Mutation	Exon	Imatinib	Sunitinib	Dasatinib	Nilotinib
E490K	9	++	+++	NE	NE
Y553N	11	+++	NE	NE	NE
W557R	11	+++	+++	NE	NE
V559A	11	+++	+++	NE	NE
V560del	11	+++	+++	+++	+++
L576P	11	+	++	++	+
P577-D579del	11	NE	NE	NE	NE
H697Y	14	+	+++	NE	NE
D820E	17	0	0	++	++

NE: not evaluated; 0: half maximal inhibitory concentration (IC₅₀) >1,000 nM, resistance; +: IC₅₀ between 500 and 1,000 nM, low sensitivity; ++: IC₅₀ between 100 and 500 nM, mid-sensitivity; +++: IC₅₀ <100 nM, high-sensitivity.